Journal of translational autoimmunity · 2025
MiR-122-5p modulates ferroptosis via SLC7A11: A potential therapeutic target in autoimmune hepatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suo Yuhong, Wang Yu, Su Yu, Wang Qianyi, Jia Jidong, Zhao Xinyan
Аннотация
BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a relatively rare cause of liver disease with a poor prognosis without intervention. Ferroptosis, a classical form of cell death, plays a crucial role in various diseases, but its role in AIH remains unclear. Therefore, we investigated the role of ferroptosis in AIH and its mechanism.
METHODS: Here, we performed extensive bioinformatic analyses using online public database and tools, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis. Ferroptosis-related assay kits, quantitative real-time polymerase chain reaction, and Western blot analysis were used to validate the results by using clinical tissues and cell samples.
RESULTS: We obtained 449 differentially expressed microRNAs (DEmiRNAs) between the control and AIH groups. Among these, hsa-miR-122-5p and hsa-miR-143-3p were screened out as potential key miRNAs by evaluating their diagnostic value, expression levels, and number of target genes. Enrichment analysis revealed a significant association between hsa-miR-122-5p and ferroptosis-related pathways. It was confirmed by in vitro assays that hsa-miR-122-5p inhibited the SLC7A11 expression, thereby promoting ferroptosis in AIH.
CONCLUSIONS: To summarize, our study demonstrated that hsa-miR-122-5p, as a potential therapeutic target, promotes ferroptosis by inhibiting the expression of SLC7A11, which provides new insights into the pathogenesis of AIH and paves the way for innovative treatment strategies.
METHODS: Here, we performed extensive bioinformatic analyses using online public database and tools, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis. Ferroptosis-related assay kits, quantitative real-time polymerase chain reaction, and Western blot analysis were used to validate the results by using clinical tissues and cell samples.
RESULTS: We obtained 449 differentially expressed microRNAs (DEmiRNAs) between the control and AIH groups. Among these, hsa-miR-122-5p and hsa-miR-143-3p were screened out as potential key miRNAs by evaluating their diagnostic value, expression levels, and number of target genes. Enrichment analysis revealed a significant association between hsa-miR-122-5p and ferroptosis-related pathways. It was confirmed by in vitro assays that hsa-miR-122-5p inhibited the SLC7A11 expression, thereby promoting ferroptosis in AIH.
CONCLUSIONS: To summarize, our study demonstrated that hsa-miR-122-5p, as a potential therapeutic target, promotes ferroptosis by inhibiting the expression of SLC7A11, which provides new insights into the pathogenesis of AIH and paves the way for innovative treatment strategies.